文献速递慢性肾脏病

达格列净对CKD进展的影响因试验前eGFR下降速率而异

Effects of Dapagliflozin on Progression of CKD According to Different Rates of Pretrial eGFR Loss.
PubMed 文献 · Clin J Am Soc Nephrol · 2025-09-09

结果显示,试验前eGFR下降更快的患者(斜率<−5 ml/min/1.73 m²/年)从达格列净中获益更显著(交互P=0.02)。

要点

  • 试验前eGFR轨迹可识别CKD进展高风险患者。
  • 快速进展者使用达格列净的肾脏保护作用更明显。
  • eGFR斜率交互作用P值均为0.02。

核心结论

  • 试验前eGFR轨迹有助于识别CKD进展风险不同及更可能从靶向干预中获益的患者。

主要发现

  • 达格列净降低总eGFR斜率的获益在试验前eGFR轨迹更陡的患者中更明显(交互P=0.02)。
  • 达格列净降低慢性eGFR斜率的获益在快速进展者中更明显(交互P=0.02)。
  • 达格列净对肾脏复合终点的获益在快速进展者中更明显(交互P=0.02)。

关键数值与推荐

  • 快速进展者定义为试验前eGFR斜率<−5 ml/min/1.73 m²/年。

临床怎么用

  • 临床可参考试验前eGFR轨迹评估CKD患者进展风险及达格列净的预期获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: eGFR slope before a clinical trial may assist in selecting participants at risk of kidney outcomes in whom new therapies are needed. In a post hoc analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease trial, we showed that the pretrial eGFR trajectory was associated with CKD progression. Patients who demonstrated rapid progression in advance of the trial experienced more pronounced benefits of dapagliflozin. BACKGROUND: Identification of patients likely to experience substantial loss of eGFR is required to detect a kidney protective treatment effect in clinical trials; this is usually achieved by restricting inclusion of patients with elevated albuminuria. However, not all patients with elevated albuminuria show progressive eGFR loss. The eGFR slope before the trial may better predict whether patients experience loss in eGFR during the trial. We assessed the effect of dapagliflozin on eGFR slope according to patients' eGFR slope before enrollment (pretrial eGFR slope) in the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease study. METHODS: We recorded eGFR data for 2 or less to 2 years from electronic medical records for 4304 patients with CKD before enrollment in the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease study. We used linear regression to estimate within-patient pre-enrollment eGFR trajectory. We evaluated the association of pre-enrollment eGFR trajectory with total and chronic eGFR slopes and a kidney composite end point. We also determined the degree to which pre-enrollment eGFR trajectory modified the effects of dapagliflozin. RESULTS: Eight hundred and seventy (20% of the total cohort) patients with three or more historical eGFR measurements were evaluated (mean [SD] pre-enrollment eGFR slope: −6.1 [6.1] ml/min per 1.73 m2/year). The benefit of dapagliflozin in reducing total (P interaction 0.02) and chronic (P interaction 0.02) eGFR slopes was more pronounced in patients with steeper preinclusion eGFR trajectory (rapid progressors; eGFR slope <−5 ml/min per 1.73 m2/year), as was the benefit of dapagliflozin on the kidney composite end point (P interaction 0.02). CONCLUSIONS: Determination of pretrial eGFR trajectory may help to identify patients with CKD at higher and lower risks of progression and those more likely to benefit from targeted intervention. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: NCT03036150

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Heerspink HJL, Chertow GM, Rossing P, et al. Effects of Dapagliflozin on Progression of CKD According to Different Rates of Pretrial eGFR Loss. Clin J Am Soc Nephrol. 2025. PMID: 41128261. doi:10.2215/CJN.0000000810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。